Growth Metrics

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q4 2018 value amounting to $6.3 million.

  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue rose 1576.44% to $6.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.3 million, marking a year-over-year increase of 1576.44%. This contributed to the annual value of $6.3 million for FY2018, which is 1576.44% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non-Current Deffered Revenue of $6.3 million as of Q4 2018, which was up 1576.44% from $6.1 million recorded in Q3 2018.
  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $10.5 million during Q4 2014, with a 5-year trough of $557000.0 in Q4 2016.
  • Its 5-year average for Non-Current Deffered Revenue is $6.3 million, with a median of $6.2 million in 2018.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 9129.01% in 2016, then surged by 87827.65% in 2017.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $10.5 million in 2014, then tumbled by 39.22% to $6.4 million in 2015, then crashed by 91.29% to $557000.0 in 2016, then soared by 878.28% to $5.4 million in 2017, then grew by 15.76% to $6.3 million in 2018.
  • Its Non-Current Deffered Revenue was $6.3 million in Q4 2018, compared to $6.1 million in Q3 2018 and $6.1 million in Q2 2018.